WASHINGTON (dpa-AFX) - Mologen AG (MGN, MGT.TO) Tuesday revealed a collaboration agreement with the University of Texas MD Anderson Cancer Center for phase I trial of its immunomodulator lefitolimod in combination with the immunotherapy Yervoy, manufactured by Bristol-Myers Squibb Co. in patients with advanced solid tumour malignancies.
The trial will evaluate lefitolimod in combination with a checkpoint inhibitor. The combination of these two immunotherapies is expected to have synergistic effects by a broader activation of the immune system. The safety of the combination will also be studied.
Furthermore, this trial aims to evaluate the efficacy of the combination of these two therapies in an expansion phase.
MD Anderson will conduct the trial with around 50-60 patients at its center in Houston Texas, US and the study will be open for patient enrollment within the next few weeks.
Copyright RTT News/dpa-AFX